Home / Business and Economy / Pharma Giant Bets Big on Untested Cancer Drug
Pharma Giant Bets Big on Untested Cancer Drug
28 Oct
Summary
- Astellas Pharma agrees to a potential $1.34 billion deal.
- The agreement is for an experimental cancer treatment from Audax.
- The treatment has not yet been tested in human subjects.
Astellas Pharma Inc. has entered into a substantial agreement with Audax Biosciences, potentially worth as much as $1.34 billion. The deal grants Astellas rights to an experimental cancer treatment originating from the Melbourne-based Audax. This experimental therapy has yet to be evaluated in human clinical trials, underscoring the pioneering approach to cancer treatment development.
Under the terms of the agreement, Audax will receive an initial upfront payment. Further financial considerations are contingent upon Astellas exercising its option to proceed with the drug's development. This significant investment reflects Astellas' commitment to advancing novel oncology therapies.
